2017-10-13T15:22:13-04:00 2016-12-31 202143072 Chet Nichols & Associates PLLC 1585 W Gaylawood Circle Salt Lake City UT 84123 990 2016-01-01 205776861 THE CHOLANGIOCARCINOMA FOUNDATION CHOL 5526 WEST 13400 SOUTH Herriman UT 84096 STACIE LINDSEY PRESIDENT 8019990455 2017-09-21 true Chet Nichols P00704962 8012622856 2017-10-13 75.169.9.104 2017-10-16 13:29:03 8711362017289uoczfgs 2017-10-16 P DEC22D5F675182A681A335151F610169048496AF DEC22D5F675182A681A335151F610169048496AF 2016 2021-01-29 14:40:06Z STACIE LINDSEY 5965 W FRAGRANT LANE Herriman UT 84096 905185 false X www.cholangiocarcinoma.org X 2006 UT To find a cure and improve the quality of life for those affected by cholangiocarcinoma. 6 5 5 350 0 0 834567 839403 1436 64300 -1921 -575 7372 1365 841454 904493 314210 229410 0 170201 270132 0 89822 293569 424343 777980 923885 63474 -19392 423222 394042 79234 66036 343988 328006 To find a cure and improve the quality of life for those affected by cholangiocarcinoma. false false 387314 4300 The Cholangiocarcinoma Foundation is committed to providing services to patients and their families affected by this devastating disease. Both patients and the professional community are educated through our Annual Conference, website and book, 100 Questions & Answers about Cholangiocarcinoma. The Foundation also provides disease education, emotional support and a multitude of resources through a discussion board, social media sites, and responses to daily calls and emails. Through initiatives such as the Patient Registry, Action Alerts, and the Biliary Information Card, patients and their caregivers are given the opportunity to participate in research efforts while being empowered to take part in their own healthcare. The Organization also partners with similar organizations to spread awareness about the challenges faced by the rare disease community. 327458 229410 60000 In 2016, the Cholangiocarcinoma Foundation awarded Research Fellowship Awards to four young investigators to raise awareness about cholangiocarcinoma and inspire innovative, quality research. In addition, a grant was awarded to the Mayo Clinic for the International Cholangiocarcinoma Research Network Biorepository (ICRN). The ICRN also hosted its first Industry Night event to parnter with pharmaceutical companies invested in cholangiocarcinoma research. The Delphi Panel was a partnership with PHAR to assemble a panel of experts to develop consensus on managing emergencies in patients with biliary stents or tubes. Their work resulted in a poster presentation at a major oncology conference and is currently undergoing review for publication in a peer-reviewed journal. The Organization continues to focus on collaborative research efforts with the medical, scientific, academic, communities, government and its non-profit partners. 714772 true true false false false false false false false false true false false false true false true false false false false false false false false false false true false false false false false false false true true false false false false false false false false false false false true 9 0 5 true false false false false false false false false false false false false false false false X 6 5 true false false false false false false true true false false true true true true true true true true false AL AR CA CT FL GA HI KS MA MD MI MN MS NC NH NJ NM NY OK OR PA RI SC TN UT VA WI WV X X X STACIE LINDSEY 8019990455 5965 W FRAGRANT LANE Herriman UT 84096 STACIE LINDSEY PRESIDENT 40.00 0.00 X X 29400 0 0 DAWN LYON VICE PRESIDENT 5.00 0.00 X X 0 0 0 LAWRENCE GOODFIELD TREASURER 5.00 0.00 X X 0 0 0 SEAN TURBEVILLE BOARD MEMBER 1.00 0.00 X 0 0 0 BRUCE COPPOCK BOARD MEMBER 1.00 0.00 X 0 0 0 JASON SCOTT BOARD MEMBER 1.00 0.00 X 0 0 0 DONNA MAYER EXECUTIVE DIRECTOR 40.00 0.00 X 78125 0 0 107525 0 0 0 false false false 839403 4946 839403 Other service revenue 900099 4300 4300 Grants returned 900099 60000 60000 64300 117 117 692 -692 -692 -692 1365 1365 1365 904493 64973 0 117 229410 229410 107525 70395 22471 14659 142750 67068 34269 41413 19857 10906 4502 4449 97412 79386 840 17186 14145 14145 7631 7631 3677 1471 735 1471 29213 20241 4751 4221 66252 43198 17852 5202 9972 8772 1200 121392 121392 17686 17686 1834 1007 416 411 2578 2578 DUES AND MEMBERSHIP 1774 1774 BANK AND MERCHANT FEES 5433 5433 MEALS 44016 43840 176 1328 518 810 923885 714772 119291 89822 268788 255517 127704 53253 20000 70000 50 4478 706 4452 10045 3998 5974 6047 295 423222 394042 27711 4754 51523 61282 79234 66036 X 323988 258006 20000 70000 343988 328006 423222 394042 -19392 3410 0 X false true X true false X 236029 315190 555393 834567 842813 2783992 236029 315190 555393 834567 842813 2783992 332516 2451476 128 88 88 127 117 548 2784540 44857 0.88040 0.85740 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false false false 10045 3998 6047 6047 PAYROLL LIABILITIES 22253 CREDIT CARD LIABILITY 39029 61282 907903 3410 3410 904493 904493 923885 923885 923885 true MAYO CLINIC 200 FIRST STREET SW Rochester MN 55905 416011702 501C3 75798 RESEARCH MASSACHUSETTS GENERAL HOSPITAL PO Box 414876 Boston MA 02241 041564655 501C3 100000 RESEARCH COLUMBIA UNIVERSITY 630 W 168th St PH 7 West New York NY 10032 135598093 501c3 50000 RESEARCH H LEE MOFFITT CANCER CENTER 12902 Magnolia Drive Tampa FL 33612 593238636 501C3 10000 RESEARCH 4 Monitoring procedures (Part I, line 2) Grants are provided to researchers focused on Cholangiocarcinoma RICK POLLOCK FORMER BOARD MEMBER 37538 WEBSITE MAINTENANCE PRINTING IT CONSULTANT false Officer directors etc family relationship Part VI line 2 Our Advocacy Director has a son who is a board member. Form 990 governing body review Part VI line 11 The Board reviewed Form 990 at a Board Meeting. Conflict of interest policy compliance Part VI line 12c Periodic reviews are conducted by the board to ensure there is no conflict of interest issues. CEO executive director top management comp Part VI line 15a Compensation of the President and other officers and key employees was discussed and evaluated and approved by the Board, These individuals were not not included in the discussion and vote of approval. The Board considered comparable wages paid by other entities to determine reasonableness of compensation. The discussion and approval of compensation was documented by the Board. Other officer or key employee compensation Part VI line 15b Compensation of other officers and key employees was discussed, evaluated and approved by the Board. These individuals were not included in the discussion and vote of approval. The Board considered comparable wages paid by other entities to determine reasonableness of compensation. The discussion and approval of compensation was documented by the Board. Governing documents etc available to public Part VI line 19 The Foundation will provide any documents required to be available to the public upon request.